Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

Progress Reports: Oregon State University: PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Superfund Research Program

PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Project Leader: David E. Williams
Grant Number: P42ES016465
Funding Period: 2013-2020
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Learn More About the Grantee

Visit the grantee's eNewsletter page Visit the grantee's eNewsletter page Visit the grantee's Twitter page Visit the grantee's Facebook page Visit the grantee's Video page

Progress Reports

Year:   2019  2018  2017  2016  2015  2014  2013 

This is the first pharmacokinetic (PK) study of the polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene (BaP), a known human carcinogen exhibiting multiple toxicities including cardiovascular, developmental, behavioral, neurocognitive, immunological and reproductive. PAHs, from combustion of carbon (coal, diesel, tobacco, wood-stoves, etc.) comprise three of the top ten chemicals of concern (the Agency for Toxic Substances and Disease Registry (ATSDR)) at priority pollutant sites and are main drivers of remediation at numerous Superfund sites. The EPA cancer risk slope factor is 1 (mg/kg-day)-1. BaP is the EPA reference compound for cancer risk assessment with PAH mixtures (Relative Potency Factor, BaP=1). Risk, as determined by EPA, drives remediation goals. Data for risk estimates are from predominantly mouse models. Utilizing UPLC-accelerator mass spectrometry (Lawrence Livermore), the research group determined absorption, metabolism and urinary excretion of [14C]-BaP after dosing human volunteers with 46 ng (5 nCi) to develop a PK model (Cross-Species and Life Stage Comparisons of PAH Dosimetry). The relative potency factor (RPF) approach was tested by co-administration of a complex PAH mixture from smoked salmon (assistance from Chemistry Core and Community Engagement Core) and the impact of genotype on metabolic profile (Hummel et al., 2018). The major findings were that there is little intra-individual variation (three separate dosings up to a year apart), BaP is rapidly absorbed and metabolized following oral dosing, and individuals exhibited distinct metabolite profiles (Madeen et al., 2018). Finally, there were no detectable BaP-DNA adducts in PBMCs (LOD 0.5 x 10^11 adducts/nucleotide) after 48-72 hours. These results can be incorporated into risk assessment models to set remediation targets that are driven by human data.

to Top